# OnCo record nct04446117 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04446117/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04446117", "NCT04446117" ;
  schema:name "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC"@en ;
  schema:alternateName "CONTACT-02"@en ;
  schema:description "A phase 3 trial of Cabozantinib, Atezolizumab, Abiraterone acetate in prostate cancer, run by Exelixis, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04446117/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04446117> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2020-10-19" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/exelixis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04446117-lancet-oncol-2025/> .